FDA Holds Off on Corcept’s Relacorilant Approval, Despite Positive Trial Results
Key Takeaway: Additional Evidence Needed for FDA Go-Ahead
Corcept Therapeutics (NASDAQ: CORT) wasn’t able to secure FDA approval for its much-anticipated drug, relacorilant, as a treatment for patients with hypertension secondary to hypercortisolism. The FDA has issued a Complete Response Letter (CRL), requesting more evidence before it can make a favorable benefit-risk judgment. This move comes even though Corcept’s pivotal GRACE trial met its main endpoint and the supporting GRADIENT trial backed up those findings.
Clinical Evidence Highlighted, but FDA Remains Cautious
The FDA’s response was clear: while the trials showed promise for relacorilant—a selective glucocorticoid receptor antagonist that controls the impact of cortisol—the agency wants further proof of effectiveness. This setback doesn’t mark the end of the road. Corcept’s CEO expressed surprise and disappointment, but reaffirmed the company’s commitment to patients, vowing to work with the FDA to find a way forward.
Pipeline and Market Outlook: What’s on the Horizon?
Relacorilant is not just a one-trick pony for Corcept. The company continues to develop this candidate for multiple uses, including ovarian cancer—where it holds an orphan drug designation in the US and Europe. The FDA has already set a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for a separate ovarian cancer indication. Additionally, Corcept has submitted a Marketing Authorization Application for relacorilant to the European Medicines Agency.
| Indication | Clinical Status | Regulatory Status | Key Dates / Milestones |
|---|---|---|---|
| Hypertension secondary to hypercortisolism | GRACE & GRADIENT trials completed | Complete Response Letter; more evidence required | Next steps to be determined after FDA meeting |
| Platinum-resistant ovarian cancer | Advanced development | PDUFA date for FDA: July 11, 2026; MAA submitted to EMA | PDUFA decision mid-2026 |
Corcept’s Strategy: Experience, Pipeline, and A Path Forward
Corcept isn’t new to this kind of regulatory setback. The company has built a robust pipeline focused on cortisol modulation for over 25 years, including more than 1,000 proprietary compounds and the already-approved drug Korlym. Their experience in navigating regulatory science, plus commitment to targeted rare disease populations, keeps them in the game—even after bumps in the road.
Investor Takeaway: Uncertain Timeline, but Multiple Shots on Goal
The FDA’s request for more data adds risk to the relacorilant story in hypercortisolism, but it’s not a dead end. Investors and observers should watch for updates on FDA meetings and see how quickly Corcept can provide new evidence. Meanwhile, the upcoming ovarian cancer milestone in 2026 and the EMA submission broaden potential opportunities. While the timing is up in the air, Corcept’s diversified pipeline and persistent approach merit continued attention.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI